Lab designation: RA3 6B2; A rat-mouse hybridoma cell line producing a monoclonal IgG2a rat AB which recognizes a B cell specific form of the T200 family of cell surface glycoproteins. B220 was first characterized by another MAB, RA3-3A1.
Researchers in Prof. Irving Weissman's laboratory have developed cell culture techniques to rapidly and efficiently derive pure populations of mesodermal cells from human pluripotent stem cells (hPSCs).
Researchers at Stanford University have discovered a novel target for the treatment of Lyme disease by blocking pathogen mimics of CD47. Lyme disease is caused by the bacterium Borrelia burgdorferi (Bb) and the current standard of care is treatment with antibiotics.
Stanford researchers in the Weissman lab have developed an engineered protein that blocks the function of the CD47 mimics pathogens use to evade the immune system.
Lab Designation: RB6 8C5; A rat-mouse hybridoma cell line producing a monoclonal IgG2b rat AB which recognizes most, if not all, granuloytes and granolucyte precursors in the mouse bone marrow.
Researchers at Stanford have developed methods to promote bone healing in people with diabetes. Diabetes is a chronic metabolic disease associated with many clinical complications including impaired bone healing.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
Stanford researchers have identified methods to phenotype and stage leukemic conditions by differential analysis of the distribution of hematopoietic stem and progenitor cell subsets in clinical hematological samples.